← Back to Clinical Trials
Recruiting NCT06456307

NCT06456307 Integration of Stepped Care for Perinatal Mood and Anxiety Disorders Among Women Attending MCH Clinics

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06456307
Status Recruiting
Phase
Sponsor Kenyatta National Hospital
Condition Depression, Anxiety
Study Type INTERVENTIONAL
Enrollment 2,970 participants
Start Date 2025-02-17
Primary Completion 2028-03

Eligibility & Interventions

Sex Female only
Min Age 14 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
Integrated Perinatal Mental health program (systematic screening for PMAD, PM+ and tele-psychiatry)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 2,970 participants in total. It began in 2025-02-17 with a primary completion date of 2028-03.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Perinatal mood and anxiety disorders (PMAD), defined as depression and anxiety during pregnancy or up to 1 year postpartum, account for substantial morbidity and mortality among birthing people globally especially in low- and middle-income countries. Several evidence-based interventions are recommended for identification and management of PMAD by non-specialist providers in resource-limited settings. This cluster-randomized trial seeks to evaluate the effect of a stepped-care intervention for screening and treatment of PMAD among perinatal women, on clinical and implementation outcomes.

Eligibility Criteria

Inclusion Criteria: * Pregnant and ≥28 weeks gestation * Attending ANC care at the facility * ≥14 years old * Screen positive for PMAD symptoms (PHQ-2≥3 and/or GAD-2≥3) * Willing to return to the MCH and PMTCT clinic for study visits Exclusion Criteria: * Less than 28 weeks gestation * Any woman at high risk of self-harm based on a study self-harm assessment protocol, * Has cognitive impairments or psychotic symptoms

Contact & Investigator

Central Contact

Nancy Ngumbau, MBChB, MPH

✉ nancym390@gmail.com

📞 +254713917226

Principal Investigator

John Kinuthia, MBChB, MMed, MPH

PRINCIPAL INVESTIGATOR

Kenyatta National Hospital

Frequently Asked Questions

Who can join the NCT06456307 clinical trial?

This trial is open to female participants only, aged 14 Years or older, studying Depression, Anxiety. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06456307 currently recruiting?

Yes, NCT06456307 is actively recruiting participants. Contact the research team at nancym390@gmail.com for enrollment information.

Where is the NCT06456307 trial being conducted?

This trial is being conducted at Nairobi, Kenya, Western Kenya, Kenya.

Who is sponsoring the NCT06456307 clinical trial?

NCT06456307 is sponsored by Kenyatta National Hospital. The principal investigator is John Kinuthia, MBChB, MMed, MPH at Kenyatta National Hospital. The trial plans to enroll 2,970 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology